TheraSense Business Model Sets Example For Small Firms – VP Huffman
This article was originally published in The Gray Sheet
Executive Summary
Leveraging core competencies and disciplined outsourcing allowed TheraSense to reach profitability rapidly, paving the way for its $1.2 bil. acquisition by Abbott, according to Larry Huffman, VP-international business development
You may also be interested in...
BD, Lilly To Continue Canadian Distribution Of Latitude
Becton Dickinson will discontinue U.S. sales of its BD Latitude diabetes management system, citing insufficient market potential for the insulin delivery pen and accompanying pen needles
Abbott Acquires A Future For Its Diabetes Care Business; Where’s Bayer?
Access to a development partnership with insulin infusion pump manufacturer Smiths Medical could prove a critical component of Abbott Labs' $1.2 bil. purchase of diabetes management firm TheraSense
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”